NHI.no
Annonse
Informasjon, tilstand

Schizofreni

Schizofreni er en alvorlig psykisk sykdom preget av hallusinasjoner og vrangforestillinger, endret tankemønster og sosial tilbaketrekking.

Schizofreni: Man tror at flere faktorer medvirker til at noen utivkler sykdommen.  Arv er en av faktorene som har betydning.

Sist oppdatert:

20. apr. 2021

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Schizofreni . Referanselisten for dette dokumentet vises nedenfor

  1. Gaughran F, Pillinger T. Schizophrenia. BMJ Best Practice, last updated 14 Jan 2021. bestpractice.bmj.com
  2. Holder SD, Wayhs A. Schizophrenia. Am Fam Physician. 2014 Dec 1;90(11):775-82. PMID: 25611712. PubMed
  3. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008; 30: 67-76. PubMed
  4. Laursen TM, Nordentoft M, Mortensen PB, Excess early mortality in schizophrenia. Annu. Rev. Clin. Psychol 2014; 10: 425-448. PubMed
  5. Kendall T, Hollis C, Stafford M, Taylor C. Recognition and management of psychosis and schizophrenia in children and young people: summary of NICE guidance. BMJ 2013; 346: f150. BMJ (DOI)
  6. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008; 30:67. PubMed
  7. Fischer BA, Buchanan RW. Schizophrenia in adults: Epidemiology and pathogenesis. UpToDate, last updated Jul 13, 2022. UpToDate
  8. Pardiñas AF, Holmans P, Pocklington AJ, et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nat Genet. 2018;50(3):381-389. PubMed
  9. Ripke S, Sanders AR, Kendler KS, et al. Genome-wide association study identifies five new schizophrenia loci. Nature Genetics 2011. doi:10.1038/ng.940.
  10. Hjorthøj C, Posselt CM, Nordentoft M. Development Over Time of the Population-Attributable Risk Fraction for Cannabis Use Disorder in Schizophrenia in Denmark. JAMA Psychiatry 2021; 78:1013. PubMed
  11. Helsedirektoratet: Nasjonal faglig retningslinje for utredning, behandling og oppfølging av personer med psykoselidelser. IS-1957. Utgitt 01.07.2013. helsedirektoratet.no
  12. Bellani M, Ricciardi C, Rossetti MG, Zovetti N, Perlini C, Brambilla P. Cognitive remediation in schizophrenia: the earlier the better?. Epidemiol Psychiatr Sci. 2019;29:e57. PubMed
  13. Woo TU. Neurobiology of schizophrenia onset. Curr Top Behav Neurosci. 2014;16:267-95. PMID: 23975845 PubMed
  14. Goldman AL, Pezawas L, Mattay VS, et al. Widespread reductions of cortical thickness in schizophrenia and spectrum disorders and evidence of heritability. Arch Gen Psychiatry 2009; 66: 467. PubMed
  15. McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia-An Overview. JAMA Psychiatry. 2020 Feb 1;77(2):201-210. PMID: 31664453. PubMed
  16. Hameed MA, Lewis AJ. Offspring of parents with schizophrenia: A Systematic Review of Developmental Features Across Childhood. Harv Rev Psychiatry. 2016 Mar-Apr;24(2):104-17. pmid: 26954595 PubMed
  17. Wang SH, Hsiao PC, Yeh LL, et al. Advanced Paternal Age and Early Onset of Schizophrenia in Sporadic Cases: Not Confounded by Parental Polygenic Risk for Schizophrenia. Biol Psychiatry. 2019;86(1):56-64. PMID: 30926130.
  18. Bernstein CN, Hitchon CA, Bolton JM, et al. Increased burden of psychiatric disorders in inflammatory bowel disease. Inflamm Bowel Dis. 2019 Jan 10;25(2):360-368 . pmid:29986021 PubMed
  19. McDonagh MS, Dana T, Selph S, et al. Treatments for Schizophrenia in Adults: A Systematic Review. Rockville (MD): Agency for Healthcare Research and Quality (US); October 2017. PMID: 29537779 PubMed
  20. Jardim PSJ, Borge TC, Johansen TB. Effekten av antipsykotika ved førstegangspsykose. Folkehelseinstituttet, Oslo 2021. www.fhi.no
  21. Tiihonen J, Mittendorfer-Rutz E, Torniainen M, et al. Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: An observational follow-up study. Am J Psychiatry 2015. PMID: 26651392 PubMed
  22. Correll CU, Galling B, Pawar A, et al. Comparison of early intervention services vs treatment as usual for early-phase psychosis: A systematic review, meta-analysis, and meta-regression. JAMA Psychiatry. 2018 May 2.
  23. Melle I, Johannesen JO, Friis S, et al. Early detection of the first episode of schizophrenia and suicidal behavior. Am J Psychiatry 2006; mai.
  24. Frankenburg FR. Schizophrenia. Medscape, last updated Sep 17, 2020. emedicine.medscape.com
  25. Haddock G, Barrowclough, Shaw JJ, et al. Cognitive-behavioural therapy v. social activity therapy for people with psychosis and a history of violence: randomised controlled trial. Bt J Psychiatry 2009; 194: 152-7. PubMed
  26. Jones C, Hacker D, Cormac I, Meaden A, Irving CB. Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia. Cochrane Database of Systematic Reviews 2012; 4: CD008712. Cochrane (DOI)
  27. De Silva MJ, Cooper S, Li HL, et al. Effect of psychosocial interventions on social functioning in depression and schizophrenia: meta-analysis. Br J Psychiatry. 2013 ;202(4):253-60. doi: 10.1192/bjp.bp.112.118018 DOI
  28. Pharoah F, Mari J, Rathbone J, et al. Family intervention for schizophrenia. Cochrane Database of Systematic Reviews 2010; 12: CD000088. Cochrane (DOI)
  29. Okpokoro U, Adams CE, Sampson S. Family intervention (brief) for schizophrenia. Cochrane Database Syst Rev. 2014 Mar 5;3:CD009802. PMID: 24595545 PubMed
  30. Rosenbaum S, Tiedemann A, Sherrington C, et al. Physical activity interventions for people with mental illness: a systematic review and meta-analysis. J Clin Psychiatry. 2014;75(9):964-74. doi: 10.4088/JCP.13r08765. DOI
  31. Daumit GL, Dalcin AT, Dickerson FB, et al. Effect of a Comprehensive Cardiovascular Risk Reduction Intervention in Persons With Serious Mental Illness: A Randomized Clinical Trial. JAMA Netw Open. 2020 Jun 1;3(6):e207247. doi: 10.1001/jamanetworkopen.2020.7247. DOI
  32. Åtgärder för att stödja personer med schizofreni att förändra ohälsosamma levnadsvanor. SBU-rapport (2015-03-11)
  33. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302: 1765-73. Journal of the American Medical Association
  34. Stroup TS, Marder S. Schizophrenia in adults: Maintenance therapy and side effect management. UpToDate, last updated Mar 23, 2022. UpToDate
  35. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013 Jun 26. doi:10.1016/S0140-6736(13)60733-3 DOI
  36. Rattehalli RD, Zhao S, Li BG, et al. Risperidone versus placebo for schizophrenia. Cochrane Database Syst Rev. 2016 Dec 15;12:CD006918. PMID: 27977041. PubMed
  37. Leucht S, Leucht C, Huhn M, et al. Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors. Am J Psychiatry 2017. pmid:28541090 PubMed
  38. Kaul I, Sawchak S, Correll CU, et al. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet. 2024;403(10422):160-170. PMID: 38104575 PubMed
  39. Jones C, Hacker D, Cormac I, Meaden A, Irving CB. Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia. Cochrane Database of Systematic Reviews 2012, Issue 4. Art. No.: CD008712. DOI: 10.1002/14651858.CD008712.pub2. DOI
  40. Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, Leucht S. Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2011, Issue 1. Art. No.: CD006626. DOI: 10.1002/14651858.CD006626.pub2. DOI
  41. Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, Kissling W, Leucht S. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2010, Issue 3. Art. No.: CD006654. DOI: 10.1002/14651858.CD006654.pub2. DOI
  42. Samara MT, Dold M, Gianatsi M, et al. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: A network meta-analysis. JAMA Psychiatry. 2016 Feb 3. doi: 10.1001/jamapsychiatry.2015.2955. DOI
  43. Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Leucht S. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2010, Issue 11. Art. No.: CD006633. DOI: 10.1002/14651858.CD006633.pub2. DOI
  44. Tiihonen J, Tanskanen A, Bell JS, et al. Long-term treatment with clozapine and other antipsychotic drugs and the risk of haematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland. Lancet Psychiatry 2022; 9: 353-362. pmid:35334224 PubMed
  45. Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies published online ahead of print, 2021 Apr 6. Lancet Psychiatry. 2021;S2215-0366(21)00039-0. PMID: 33862018. PubMed
  46. Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis. Schizophr Bull. 2013;39(2):306-318. PubMed
  47. Wu RR, Jin H, Gao K, et al. Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study. Am J Psychiatry 2012; 169: 813-21. American Journal of Psychiatry
  48. Bighelli I, Huhn M, Schneider-Thoma J, et al. . Response rates in patients with schizophrenia and positive symptoms receiving cognitive behavioural therapy: a systematic review and single-group meta-analysis. BMC Psychiatry 2018; 18(1): 380. pmid:30514268 PubMed
  49. Penney D, Sauvé G, Mendelson D, et al. Immediate and Sustained Outcomes and Moderators Associated With Metacognitive Training for Psychosis A Systematic Review and Meta-analysis. JAMA Psyciatry 2022. pmid:35320347 PubMed
  50. Xia J, Merinder LB, Belgamwar MR. Psychoeducation for schizophrenia. Cochrane Database of Systematic Reviews 2011, Issue 6. Art. No.: CD002831. DOI: 10.1002/14651858.CD002831.pub2. DOI
  51. Gorczynski P, Faulkner G. Exercise therapy for schizophrenia. Cochrane Database Syst Rev. 2010 May 12;(5):CD004412. doi: 10.1002/14651858.CD004412.pub2. Pmid 20464730 www.cochranelibrary.com
  52. Pearsall R, Smith DJ, Pelosi A, Geddes J. Exercise therapy in adults with serious mental illness: a systematic review and meta-analysis. BMC Psychiatry 2014 Apr 21. pmid:24751159 PubMed
  53. Dauwan M, Begemann MJ, Heringa SM, et al. Exercise Improves Clinical Symptoms, Quality of Life, Global Functioning, and Depression in Schizophrenia: A Systematic Review and Meta-analysis. Schizophr Bull 2016 May; 42(3): 588-99. pmid:26547223 PubMed
  54. Helsedirektoratet. Nasjonal faglig retningslinje om bruk av elektronkonvulsiv behandling - ECT. IS-2629. Oslo: Helsedirektoratet 2017. helsedirektoratet.no
  55. Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia. Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No.: CD000076. DOI: 10.1002/14651858.CD000076.pub2. DOI
  56. Amminger GP, Schäfer MR, Schlögelhofer , et al. Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study. Nat Commun 2015; 6: 7934. doi:10.1038/ncomms8934 DOI
  57. Heilbronner U, Samara M, Leucht S, Falkai P, Schulze TG. The Longitudinal Course of Schizophrenia Across the Lifespan: Clinical, Cognitive, and Neurobiological Aspects. Harv Rev Psychiatry. 2016;24(2):118-128. PMID: 26954596. PubMed
  58. Hor K, Taylor M. Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol 2010; 24:81. PubMed
  59. Bai W, Liu ZH, Jiang YY, et al. Worldwide prevalence of suicidal ideation and suicide plan among people with schizophrenia: a meta-analysis and systematic review of epidemiological surveys. Transl Psychiatry. 2021;11(1):552. PubMed
  60. Dold M, Li C, Tardy M, Khorsand V, Gillies D, Leucht S. Benzodiazepines for schizophrenia. Cochrane Database of Systematic Reviews 2012, Issue 11. Art. No.: CD006391. DOI: 10.1002/14651858.CD006391.pub2. DOI
  61. Thornicroft G, Brohan E, Rose D, Sartorius N, Leese M, for the INDIGO Study Group. Global pattern of experienced and anticipated discrimination against people with schizophrenia: a cross-sectional survey. Lancet 2009; 373: 408-15. PubMed
  62. Ayano G, Tesfaw G, Shumet S. The prevalence of schizophrenia and other psychotic disorders among homeless people: a systematic review and meta-analysis. BMC Psychiatry. 2019 Nov 27;19(1):370. PMID: 31775786 PubMed
  63. Olfson M, Gerhard T, Huang C, Crystal S, Stroup TS. Premature Mortality Among Adults With Schizophrenia in the United States. JAMA Psychiatry. 2015;72(12):1172-1181. PubMed
  64. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360: 225-35. New England Journal of Medicine
  65. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007; 64: 1123-31. PubMed
  66. Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry 2017; 74:686. PubMed
  67. Tsuda Y, Saruwatari J, Yasui-Furukori N. Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine. BMJ Open. 2014 Mar 4;4(3):e004216. PMID: 24595134 PubMed
Annonse
Annonse